Kalaris Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview

Kalaris Therapeutics

07/08/2026 18:04

Kalaris Therapeutics Inc KLRS.OQ KLRS.O is expected to  show no change in quarterly revenue when it reports  results on August 11 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Kalaris Therapeutics Inc is for a loss of 49 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Kalaris Therapeutics Inc is $18.50, about 341.5% above its last closing price of $4.19
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.51
-0.52
-0.46
Beat
12.1
Dec. 31 2026
-0.27
-0.53
-0.51
Beat
4
Sep. 30 2025
-0.65
-0.65
-0.64
Beat
2​
Jun. 30 2025
-0.53
-0.52
-0.61
Missed
-17.3
​​Mar. 31 2025
-0.75
-0.77
-2.52
Missed
-225.2
​
Jun. 30 2024
-1.61
-2.41
-1.15
Beat
52.4
This summary was machine generated August 7 at 17:04 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)